Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia

scientific article published in January 2002

Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1048060148
P356DOI10.1385/MO:19:2:79
P698PubMed publication ID12180484

P50authorJan PalmbladQ65768736
P2093author name stringJ Westin
M Björkholm
B Markevärn
J Kutti
M Merup
N Mauritzson
C Maim
G Birgergård
Swedish National Study Group on Chronic Myeloproliferative Disorders
P2860cites workThalidomide is an inhibitor of angiogenesisQ24563363
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.Q33338281
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelinesQ33773400
Antitumor activity of thalidomide in refractory multiple myelomaQ33880642
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.Q34503538
Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularityQ35745897
Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasiaQ41114232
Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disordersQ41618119
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularizationQ42547622
Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myelomaQ43503967
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.Q43700135
Thalidomide in agnogenic and secondary myelofibrosisQ43795704
Reversal of myelofibrosis by hydroxyureaQ44986162
Life expectancy of patients with chronic nonleukemic myeloproliferative disordersQ70138586
Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasiaQ73458297
P433issue2
P921main subjectthalidomideQ203174
myelofibrosisQ1752571
P304page(s)79-86
P577publication date2002-01-01
P1433published inMedical OncologyQ2152666
P1476titleNegligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia
P478volume19

Reverse relations

cites work (P2860)
Q50477923Ex vivo activity of thalidomide in childhood acute leukemia.
Q93085740Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019
Q39244371How I treat splenomegaly in myelofibrosis
Q35964242New approaches in the treatment of myelofibrosis
Q33389330New drugs for the treatment of myelofibrosis
Q36157668Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study
Q36604028Ruxolitinib for myelofibrosis
Q42090824Ruxolitinib for the treatment of myelofibrosis: its clinical potential
Q33359542Thalidomide for the treatment of idiopathic myelofibrosis
Q83049404Thalidomide therapy for myelofibrosis with myeloid metaplasia
Q37860336Therapeutic approaches in myelofibrosis.

Search more.